A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma

被引：1
|
作者：
Xu, Rui-hua
Sun, Guo-ping
Lu, Hui-shan
Peng, Liu Yun
Xu, Jian-ming
Zhong, Mei-zuo
Zhang, He-long
Yu, Shi-ying
Li, Wei
Hu, Xiao-hua
Wang, Jie Jun
Cheng, Ying
Zhou, Jun-tian
Guo, Zeng-qing
Guan, Zhongzhen
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] An Hui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China
[3] Fujian Med Univ, Union Hosp, Dept Surg Oncol, Shanghai, Peoples R China
[4] China Med Univ, Hosp 1, Shenyang, Peoples R China
[5] Chinese Peoples Liberat Army 307 Hosp, Dept Oncol, Beijing, Peoples R China
[6] Central South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[7] Fourth Liberat Army Univ, Tangdu Hosp, Dept Oncol, Xian, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan 430074, Peoples R China
[9] Jilin Univ, Affiliated Hosp 1, Dept Oncol, Changchun, Jilin, Peoples R China
[10] Guangxi Zhuang Autonomous Reg Tumor Hosp, Dept Oncol, Nanning, Peoples R China
[11] Shanghai Chong Zhen Hosp, Shanghai, Peoples R China
[12] Jilin Prov Canc Hosp, Changchun, Peoples R China
[13] Tumor Hosp Hunan Prov, Dept Oncol, Changsha, Hunan, Peoples R China
[14] Tumor Hosp Fujian Prov, Dept Oncol, Fuzhou, Peoples R China
[15] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4025
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Boku, Narikazu
    Yamamoto, Seiichiro
    Fukuda, Haruhiko
    Shirao, Kuniaki
    Doi, Toshihiko
    Sawaki, Akira
    Koizumi, Wasaburo
    Saito, Hiroshi
    Yamaguchi, Kensei
    Takiuchi, Hiroya
    Nasu, Junichiro
    Ohtsu, Atsushi
    LANCET ONCOLOGY, 2009, 10 (11): : 1063 - 1069
  • [22] Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
    W Koizumi
    K Yamaguchi
    H Hosaka
    Y Takinishi
    N Nakayama
    T Hara
    K Muro
    H Baba
    Y Sasaki
    T Nishina
    N Fuse
    T Esaki
    M Takagi
    M Gotoh
    T Sasaki
    British Journal of Cancer, 2013, 109 : 2079 - 2086
  • [23] Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).
    Yamada, Yasuhide
    Boku, Narikazu
    Mizusawa, Junki
    Iwasa, Satoru
    Kadowaki, Shigenori
    Nakayama, Norisuke
    Azuma, Mizutomo
    Sakamoto, Takeshi
    Shitara, Kohei
    Okuno, Tatsuya
    Chin, Keisho
    Nozaki, Akira
    Nakamura, Masaki
    Hara, Hiroki
    Katayama, Hiroshi
    Fukuda, Haruhiko
    Yoshikawa, Takaki
    Sano, Takeshi
    Sasako, Mitsuru
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.
    Xu, Rui-hua
    Wang, Zhi-Qiang
    Shen, Lin
    Wang, Wei
    Lu, Jian-Wei
    Dai, Guanghai
    Xu, Jian-Ming
    Zhang, Yan-Qiao
    Chen, Xiao-Bing
    Deng, Yan-Hong
    Zhao, Yun-Bo
    Fan, Nan-Feng
    Yu, Gengsheng
    Liao, Wangjun
    Yuan, Xia
    Lin, You-En
    Liu, Guo-Long
    Zou, Qing-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Erratum: Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
    W Koizumi
    K Yamaguchi
    H Hosaka
    Y Takinishi
    N Nakayama
    T Hara
    K Muro
    H Baba
    Y Sasaki
    T Nishina
    N Fuse
    T Esaki
    M Takagi
    M Gotoh
    T Sasaki
    British Journal of Cancer, 2014, 111 : 2382 - 2382
  • [26] S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Yamaguchi, Kensei
    Moriwaki, Toshikazu
    Komatsu, Yoshito
    Nishina, Tomohiro
    Tsuji, Akihito
    Nakajima, Takako Eguchi
    Gotoh, Masahiro
    Machida, Nozomu
    Bando, Hideaki
    Esaki, Taito
    Emi, Yasunori
    Sekikawa, Takashi
    Matsumoto, Shigemi
    Takeuchi, Masahiro
    Boku, Narikazu
    Baba, Hideo
    Hyodo, Ichinosuke
    LANCET ONCOLOGY, 2016, 17 (01): : 99 - 108
  • [27] Clinical Study of S-1 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-Line Treatment for Elderly Patients with Advanced Gastric Cancer
    Bo Deng-feng
    Hu Xiu-fu
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2015, 3 (04): : 238 - 242
  • [28] A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
    Kang, Y.
    Chin, K.
    Chung, H.
    Kadowaki, S.
    Oh, S.
    Nakayama, N.
    Lee, K.
    Hara, H.
    Chung, I.
    Tsuda, M.
    Park, S.
    Hosaka, H.
    Hironaka, S.
    Miyata, Y.
    Ryu, M.
    Takeuchi, M.
    Baba, H.
    Hyodo, I.
    Bang, Y.
    Boku, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
    Boku, Narikazu
    Muro, Kei
    Machida, Nozomu
    Hashigaki, Satoshi
    Kimura, Nobuyuki
    Suzuki, Mie
    Lechuga, Mariajose
    Miyata, Yoshinori
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 261 - 270
  • [30] Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer
    Yamaguchi, Kensei
    Fuse, Nozomu
    Komatsu, Yoshito
    Fujii, Hirofumi
    Hironaka, Shuichi
    Omuro, Yasushi
    Muro, Kei
    Yasui, Hirofumi
    Ueda, Shinya
    Nishina, Tomohiro
    Watanabe, Morihiro
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 879 - 885
12345